

WFS1 K186N — Wolframin

Lysine → Asparagine at position 186. N-terminal cytoplasmic (intrinsically disordered). ClinVar Uncertain significance, AlphaMissense 0.871, DynaMut2 $\Delta\Delta G$ -0.45 kcal/mol (destabilising).

IDENTITY

Variant	K186N (p.Lysine186Asparagine)
DNA change	c.558G>C
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV001180254
Amino acid change	Lysine (K) → Asparagine (N)

STRUCTURAL CONTEXT

AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 186	84.31 HIGH CONFIDENCE
Domain	N-terminal cytoplasmic (intrinsically disordered)
Position context	N-terminal cytoplasmic (intrinsically disordered)
IDR flag	No — pLDDT well above 50 threshold

Position 186 sits in N-terminal cytoplasmic (intrinsically disordered). The wild-type residue is positively charged (lysine — primary amine); the mutant is polar amide (asparagine — H-bond donor/acceptor). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.

COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE

0.871am_class: **likely pathogenic** —
threshold > 0.564DYNAMUT2 $\Delta\Delta G$ **-0.45** kcal/molDestabilising · Job
178092109689

PLDDT (ALPHAFOLD)

84.31

high confidence

CLINICAL EVIDENCE

ClinVar classification	UNCERTAIN SIGNIFICANCE
Review status	criteria provided, single submitter
Last evaluated	2019/01/21 00:00
Inheritance	Inheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations.
WFS1 variant landscape	K186N is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 in ClinVar)
	<ul style="list-style-type: none"> (no conditions catalogued)

RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$ + binding site affected → CATEGORY 3 – docking experiments $\Delta\Delta G 2-4$ → CATEGORY 2 – pharmacological chaperones $\Delta\Delta G > 4$ → CATEGORY 1 – gene therapy pLDDT < 50 → CATEGORY 5 – IDR, experimental only Stable fold + functional site hit → CATEGORY 4 – site-specific docking

Category 3/4 — Most Druggable

$|\Delta\Delta G|=0.45 < 2$ kcal/mol (fold intact) + AlphaMissense 0.871 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Wolframin's fold survives this substitution ($|\Delta\Delta G|=0.45$ kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.871. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.